Adicet Bio, Inc. (ACET) Stock

Adicet Bio, Inc. (ACET) is a Healthcare stock trading at $9.19 (as of 2026-08-21), with a market capitalization of $85.86M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Understand Adicet Bio, Inc.: how it makes money

Adicet Bio develops allogeneic gamma delta T cell therapies for cancer and other diseases, including ADI-001 in Phase I, and it would generate value by advancing these product candidates toward clinical completion and potential commercialization.

Adicet Bio’s profit model depends on whether its engineered allogeneic gamma delta T cell therapy candidates, led by ADI-001 in Phase I, successfully progress through clinical development toward eventual commercialization.

Business quality (Weak): Clear scientific focus and a named lead program (ADI-001 in Phase I), but limited disclosed reportable segments and operational KPIs provided are disease-area specific to lupus measures rather than the described lymphoma indication.

Bull case

Lead candidate has entered early clinical study: ADI-001 is in Phase I for the treatment of non-Hodgkin's lymphoma.
Therapy platform is designed for targeted and durable immune activity: Its gamma delta T cells are engineered with chimeric antigen receptors and T cell receptor-like antibodies to support selective tumor targeting, innate and adaptive anti-tumor immune response, and enhanced persistence for durable activity.
Pipeline extends beyond the lead program: The company is also developing ADI-002.

Bear case

Clinical and regulatory outcomes are highly uncertain at Phase I: With ADI-001 in Phase I, the program faces the risk that it may not demonstrate the needed clinical results to advance further.
Operational KPIs provided do not directly match the described lead indication: The listed operating metrics are lupus nephritis and systemic lupus erythematosus disease activity measures, while ADI-001 is described for non-Hodgkin's lymphoma.
Limited visibility into revenue drivers: No official reportable segments or segment revenue candidates were provided, which limits clarity on how the business would translate clinical progress into near-term earnings.

Valuation — source: SEC EDGAR (first-party)
Price	$9.19
Market Cap	$85.86M
Price / Book	0.71
Price / Sales	17.09
FCF Yield	-187.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$5.78M
Net Margin	-2021.9%
Revenue Growth (YoY)	-46.1%
EPS Growth (YoY)	1174.4%
FCF Growth (YoY)	3.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-4.11 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($8.05M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Brian Nicholas Harvey
Employees	152
Country	US
IPO Date	2018-03-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.